Skip to main content
. Author manuscript; available in PMC: 2020 May 13.
Published in final edited form as: Oncogene. 2019 Nov 13;39(8):1619–1633. doi: 10.1038/s41388-019-1097-7

Figure 6: SIRT3 and SOD2 are required for successful metastasis to the omentum.

Figure 6:

A. Representative tumor luminescence images of NSG mice injected with SK-OV-3-luciferase cells transfected with either scramble siRNA, siRNA targeting SIRT3 or SOD2. B. Western blot demonstrating knock down of SIRT3 and SOD2 three days after transfection. C. Quantification of whole animal tumor luminescence over time (n=7–8; Mixed-design ANOVA P=0.004, Dunnett’s multiple comparisons test *P < 0.05, **P < 0.01, ****P < 0.0001). D. Assessment of the peritoneal cavity revealed that the majority of SK-OV-3 tumors (black arrows) were localized to the omentum. E. H & E staining demonstrates that SIRT3 and SOD2 knock down abrogate tumor burden in the omentum. F. SIRT3 and SOD2 knock down decreases omental weight and G. number of tumors per longitudinal section of omentum assessed by H & E (One way ANOVA, F: P = 0.01, G: P < 0.0001; Tukey’s multiple comparisons test *P < 0.05, P < 0.0001). H. Variability in individual omental tumor sizes between experimental groups (violin plot, median + interquartile range).